THAP11

Across TCGA pan-cancer cohorts, THAP11 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated THAP11 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher THAP11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated THAP11 expression acts as an unfavorable survival marker.

HNSC, SARC, and SKCM are the cancer types where THAP11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.178	0.752	<.001	48	view →
SARC	DFS	Median	All	0.038	0.611	<.001	12	view →
SKCM	OS	Median	All	0.236	0.787	.005	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

THAP11–HNSC (OS)

Open the HNSC breakdown →